The impact of an aggressive local control policy and of adjuvant chemotherapy in primary presentation extremity adult soft-tissue sarcoma in sequential cohorts over 20 years at the Princess Margaret Hospital

James Metz, MD
OncoLink Associate Editor
Ultima Vez Modificado: 25 de octubre del 2000

Translation for this article does not exist


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

Soft Tissue Sarcoma Therapy Limb Salvage Rate 81 Percent

Sep 22, 2011

Tumor necrosis factor-α, melphalan-based isolated limb perfusion benefits amputation candidates

FDA Approves Yondelis for Soft-Tissue Sarcoma

Oct 25, 2015

Drug sanctioned for liposarcoma or leiomyosarcoma

Pazopanib Active in Metastatic Soft-Tissue Sarcoma

May 17, 2012

Progression-free survival up in metastatic non-adipocyte soft-tissue sarcoma, after chemo